Press Release FeedGet the RSS feed
Menu

Business Wire

ADOCIA Announces a €7 Million Financing and the Extension of Its Cash Runway to 2028

Business Wire

  • Capital increase for a total gross amount of €3 million through the issue of a total number of 1,477,934 new ordinary shares, at a price of €2.04 per share

  • Participation of all of the Company's directors and of its Chief Executive Officer, as well as of a limited number of historical investors

  • €4 million increase of the shareholder loan agreement signed with Vester Finance on April 21, 2026, repayable in new shares or in cash

  • Cash runway extended to Q1 2028 thanks to this financing transaction combined with cost reductions. Objective of bridging to the $20m milestone payment for the marketing authorization approval of BC Lispro in China, providing financial visibility until 2029

LYON, France, October 20, 2026--Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the "Company"), today announced that it has obtained two financings: on the one hand, the issue of ordinary shares to a limited number of investors, including the directors and its chief executive officer, by way of a capital increase with cancellation of shareholders' preferential subscription rights (the "Capital Increase") and, on the other hand, the signing of an amendment to the shareholder loan agreement signed with Vester Finance in April 2026 (the "Amendment to the Agreement") (together, the "Financing Transaction").

Use of proceeds

As of today, the Company's cash position is €8.4 million, which enables it to finance its activities until the beginning of the second quarter of 2027, excluding the proceeds of this Financing Transaction and revenue from existing or future partnerships.

This Financing Transaction, taking into account the full utilization of the shareholder loan agreement, as well as the cost reductions initiated by the Company since September 20261, enables the Company to extend its cash runway until Q1 2028. Given this revised cash runway, the Company is expected to reach the milestone payment of $20 million, subject to the marketing authorization approval of BC Lispro in China. In this scenario, the cash runway would be extended to 2029.

The uncertainty relating to the going concern mentioned in the 2026 half-year report is thus removed.

This Financing Transaction enables the Company to:

  • Step up the promotion of its BioChaperone® technology to sign partnerships. The Company has already invested in the manufacturing of BC222 batches for the commercial launch of BioChaperone® Lispro over the first two years in China and of BC449 GMP batches for BioChaperone® collaborations.

  • Pursue the development of its AdoXLong™ platform to progress towards clinical development.

  • Finance the Company's general corporate purposes

  1. ExtelJ.P. Morgan Stays Top of Extel’s All-America Equities Research TableExtel's 55th annual survey reveals J.P. Morgan, BofA Securities and Morgan Stanley as the top US research providers. Jefferies leads the analyst leaderboard with BofA and Evercore tied for second. NEW YORK, October 20, 2026--Extel, the leading provider of market sentiment in the financial industry, has
  2. Pernod Ricard Announces the Launch of a Tender Offer on Seven Existing Series of Notes Maturing in September 2027, October 2027, November 2028, April 2030, November 2030, March 2032 and November 2032, and Announces Its Intention ...PARIS, October 20, 2026--Pernod Ricard Announces the Launch of a Tender Offer on Seven Existing Series of Notes Maturing in September 2027, October 2027, November 2028, April 2030, November 2030, March 2032 and November 2032, and Announces Its Intention to Issue New Deeply Subordinated Notes Regulator
  3. European Wealth Firms Build Private Markets Capability Faster Than They Communicate It, Peregrine Report FindsCapability outpaces communication: 73% of the 30 firms show visible private markets engagement, yet only 40% have a dedicated landing page explaining it to clients Swiss private banks set the benchmark: 70% maintain dedicated private markets destinations, led by Julius Baer, UBP, Pictet and Lombard Odier Visibility is con
  4. Kyckr appoints new Head of Product to spearhead service expansionJack Rawden will lead product expansion across risk signals, registry intelligence and perpetual KYB The appointment continues the reshaping of Kyckr's senior team under CEO Steve Lamb, following the appointment of Ian Jones as Chief Technology Officer Kyckr has been named a Category Leader for KYC Data Solutions by Chart
  5. FinanceAugust Breaks UK Credit Card Record as Balances SoarFICO UK Credit Card Market Report suggests risk teams must closely monitor payment rates and overlimit usage as rising inflation adds to financial pressure for consumers LONDON, October 20, 2026--According to data analysis from global analytics software leader FICO (NYSE: FICO), average active UK credi
  6. AIOnly 8% of insurance BPO users would renew their contracts as-isInsurance outsourcing contracts are being reopened as buyers seek AI-led efficiency and stronger strategic value. HAMILTON, Bermuda, October 20, 2026--Only 8% of surveyed insurance organizations using business process outsourcing (BPO) would renew their contracts as-is. Among the 110 BPO users in the s